Vaccination against communicable diseases is crucial for disease prevention, but this practice poses challenges to healthcare professionals in patients with haemophilia.
| INTRODUC TI ON
The prevention of communicable diseases by vaccination has been a major public health success over the past century. [1] [2] [3] However, vaccination of patients with severe congenital bleeding disorders remains a challenge, and clinicians are often uncertain about immunization recommendations for these patients.
Haemophilia, caused by the deficiency of coagulation factor VIII (haemophilia A) or coagulation factor IX (haemophilia B), is the most common severe congenital bleeding disorder. A number of issues related to vaccination of patients with haemophilia remain controversial, including the immunogenicity and tolerability of off-label subcutaneous administration of vaccines, 9 and the risk of inhibitor formation with vaccination in patients receiving coagulation factor replacement therapy. 5, 10 The risk of bleeding in patients with coagulation disorders needs to be carefully evaluated before intramuscular administration of any vaccine, and the subcutaneous route should only be used if the efficacy is similar to that of the intramuscular route. 11 Most experts agree that individuals with haemophilia should be vaccinated according to the schedule for the general population, and that subcutaneous vaccine administration is preferred over the intramuscular route when feasible. 
| ME THODS
A modified Delphi consensus [15] [16] [17] Once validated by external reviewers, the statements were submitted to clinicians operating at haemophilia centres across Italy using a secure website (http://www.progettoheva.it). The clinicians expressed their level of agreement/disagreement on each statement anonymously using a 5-point Likert-type scale (1 = strongly disagree, 2 = disagree, 3 = somewhat agree, 4 = agree and 5 = strongly agree). 
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Consensus was considered to be reached when the sum for disagreement or agreement was ≥66%.
Statements without consensus were discussed by the steering committee during a second meeting (Milan, April 2018 ) and subjected to a second round of evaluation by the participants of the first Delphi round, using the online system. Finally, a series of practical consensus recommendations were drafted based on the results from the Delphi process.
| RE SULTS

| Delphi process
A PubMed search of the peer-reviewed literature published in English until 30 August 2017 (Table 1) identified 985 potentially relevant articles; 966 were excluded after reviewing the title and the abstract ( Figure 1 ). The main reasons for exclusion were (publication prior to 1970) articles describing animal studies, haemophilia-related articles unrelated to vaccination, studies lacking statistical power and articles that were poorly written. The full texts of the remaining 19 articles (plus 1 article that was published after completion of the literature search) were selected for discussion at the first meeting (Table S1 ). (Table 2) .
During the first round of consensus development, 83 participants (including the steering committee) evaluated 27 statements and reached consensus on 22, agreement on 13 and disagreement on nine ( Table 2 ). The five statements on which no consensus was reached were concerned with the timing of vaccination in relation to the administration of coagulation factor replacement therapy ( 
2.2
There is no evidence that the vaccines delivered by the intramuscular route are more effective than those administered subcutaneously 82% agreement -
2.3
Antibody titration should not be performed before vaccination in patients with haemophilia 71% agreement -
2.4
If intramuscular administration of vaccine is mandatory, it is advisable for patients with haemophilia to receive factor replacement prior to vaccination
No consensus No consensus
2.5
The routine application of ice to the injection site is recommended before and after vaccine administration in patients with haemophilia 93% agreement -
2.6
Rubbing of the injection site should be avoided in patients with haemophilia; instead, compression at the injection site is recommended 98% agreement -
2.7
When vaccinating patients with haemophilia, use the thinnest possible needle 94% agreement -
Vaccinating subgroups of patients with haemophilia
3.1
The use of live attenuated vaccines is contraindicated in immunocompromised a patients with haemophilia 84% agreement -
3.2
Immunocompromised a patients with haemophilia should be vaccinated against pneumococcus and influenza 94% agreement -
3.3
Patients with haemophilia who are travelling to areas where yellow fever and/or typhus are endemic should be vaccinated against these diseases 94% agreement -
3.4
Patients with haemophilia aged ≥65 years should be vaccinated against pneumococcus and influenza as per the institutional vaccination schedule 99% agreement -
3.5
The administration of hyposensitizing therapy by subcutaneous and/or intradermal route is not contraindicated in patients with haemophilia and atopy
schedules may vary between countries; those issued by the Italian
Ministry of Health are summarized in Table S2 .
Vaccine administration in patients with haemophilia
2.1 Subcutaneous administration of vaccines is preferred over intramuscular administration in patients with haemophilia, regardless of disease severity, to reduce the risk of bleeding (83% consensus).
2.2 There is no evidence that vaccines delivered by the intramuscular route are more effective than those administered subcutaneously (82% consensus). 
5.3
There is evidence that vaccination can compromise the efficacy of immune tolerance induction therapy in patients with haemophilia and inhibitors 77% disagreement -
5.4
All types of vaccination should be postponed in haemophilia patients with inhibitors who are undergoing immune tolerance induction therapy until there is a complete response to immune tolerance 75% disagreement -a Patients receiving biologic therapy; patients with HIV aged >5 years with CD4+ count <200; patients with HIV aged 1-5 years with CD4+ count <500; patients with HIV aged <1 year with CD4+ count <750.
TA B L E 2 (Continued)
| 661 SANTAGOSTINO eT Al. with haemophilia should receive booster doses by the standard schedule, without reference to antibody coverage (71% consensus).
2.5
The routine application of ice to the injection site is recommended before and after vaccine administration in patients with haemophilia (93% consensus).
2.6 Compression of the injection site is recommended after vaccination of patients with haemophilia; rubbing the injection site should be avoided (98% consensus).
2.7 When vaccinating patients with haemophilia, a needle with the smallest possible gauge should be used (94% consensus).
The group agreed (>90% consensus) with the currently recommended protocol for administering vaccines intramuscularly to individuals with bleeding disorders, which involves applying an ice pack to the injection site before and after vaccination, using the smallest gauge needle available, and applying firm pressure to the injection site without rubbing, for ≥5 minutes after vaccination.
20
Some discrepancies exist in the recommendations regarding the route of vaccination in patients with bleeding disorders, 20, 21 with concerns that the subcutaneous route may not provide the same level of immunogenicity as intramuscular administration.
20,22,23
Studies have shown that subcutaneous injections were associated with vaccine failure due to lower rates of seroconversion, the effect being more pronounced in elderly patients. Choosing the subcutaneous route is not always possible because some vaccines are only suitable for intramuscular use.
Evidence supporting the prophylactic administration of coagulation factor concentrate before intramuscular vaccine administration is lacking. During the first consensus round, the participants were not in agreement about this practice, with 54% of the participants agreeing on the need to administer a clotting factor concentrate before intramuscular vaccine administration to minimize the risk of muscle haematoma (statement 2.4, Table 2 ). The lack of consensus persisted after the second round, when 50% agreed and 50% disagreed.
It was previously thought that administering factor VIII at the same time as a vaccine increased the risk of inhibitor development in patients with severe haemophilia. However, this is no longer considered to be true, and the Medical and Scientific Advisory Council of the US National Hemophilia Foundation recommends that patients may be given prophylactic factor replacement within 1 day after intramuscular vaccination to decrease the risk of injection site haematoma. 
Vaccination for subgroups of patients with haemophilia
Immunocompromised individuals
The use of live attenuated vaccines is contraindicated in immu-
nocompromised patients with haemophilia (84% consensus).
Immunocompromised patients with haemophilia should be vaccinated against pneumococcus and influenza (94% consensus).
A substantial number of adults with haemophilia are human immunodeficiency virus (HIV)-positive due to blood products received before routine screening of donated blood began. 13 In this vulnerable population, vaccination against preventable disease is fundamental to avoid co-infections that may have particularly detrimental effects. ; more recent studies did not confirm these results.
28-32
International guidelines consistently recommend vaccination of HIVpositive individuals using inactivated vaccines. Live vaccines are not recommended in adults with a CD4 count <200 cells/mm 3 , but are feasible and safe when the CD4 count is ≥200 cells/mm 3 .
33-36
For the present consensus, immunocompromised individuals were defined as patients receiving biologic therapy, and patients with HIV infections and low CD4+ T lymphocyte counts (<200 cells/ Improved care and access to safe factor replacement products have substantially increased the life expectancy of patients with haemophilia, 37, 38 resulting in the need to manage age-related diseases in this population. Current guidelines recommend immunizing people aged ≥65 years against pneumonia, influenza and herpes zoster. These vaccinations can also be given to elderly patients with haemophilia based on the available evidence showing that older adults vaccinated against influenza or pneumococcal disease have a lower risk of developing these illnesses compared with unvaccinated age-matched individuals.
39,40
Atopic patients 3.5 The use of hyposensitizing therapy administered by the subcutaneous or intradermal route is not contraindicated in atopic patients with haemophilia (92% consensus).
Vaccination and the risk of inhibitor development in patients with haemophilia
4.1 There is insufficient scientific evidence supporting the association between vaccination of patients with haemophilia and development of neutralizing antibodies (inhibitor) against the deficient factor (84% consensus).
4.2 There is no need to avoid vaccination in association with the administration of the replacement therapy with the deficient factor (on the same day) in patients with haemophilia to prevent inhibitor development (70% consensus).
There is no need to delay administration of prophylactic therapy
with the deficient factor by at least 24 hours after vaccination in patients with haemophilia (66% consensus).
with the deficient factor by at least 48 hours after vaccination in patients with haemophilia (75% consensus). Few studies have investigated the potential effect of vaccination on inhibitor formation, and the generalizability of these studies is limited by small sample size and short follow-up duration.
41
A pilot study comparing an early versus standard prophylaxis regimen in previously untreated severe haemophilia A patients (n = 26)
reported a significantly lower risk of inhibitor formation with early versus standard prophylaxis.
The timing of vaccination relative to factor VIII infusion may be relevant, but data from the PedNet Registry suggested otherwise.
18
This study compared the risk of inhibitor development between previously untreated patients with severe haemophilia (n = 375) who did and did not receive vaccinations within 24, 72 or 120 hours of factor VIII infusion, 18 and found that vaccination administered close to factor VIII exposure did not increase the risk of inhibitor formation. 
| CON CLUS I ON S AND PER S PEC TIVE S
This article describes issues that may be of interest not only to haemophilia experts, but also to general practitioners, paediatricians and healthcare professionals at vaccination centres in Italy, and provides consensus-based recommendations in key areas of uncertainty (Table 3) . Participants agreed on most statements, except those addressing the potential role of vaccination in inhibitor formation.
Available data showed no association between vaccination and the risk of inhibitor development, and the final consensus statements of HEVA study reflect these data.
The overall results of the HEVA consensus suggest that patients with haemophilia should receive vaccinations according to the institutional schedule for individuals without bleeding disorders. The only difference is that vaccination of patients with haemophilia requires comprehensive planning, taking into account in these patients. It should also be noted that these recommendations were designed by Italian experts using the Delphi consensus method, which might affect their generalizability to a broader patient population.
It is hoped that these evidence-and consensus-based recommendations will provide valuable guidance for clinicians and healthcare professionals involved in the vaccination of patients with haemophilia.
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No. Statement
Consensus degree (%)
Vaccination of patients who have already developed inhibitors
5.1
In patients with haemophilia and inhibitors, there is no evidence that any type of vaccination should be postponed until the levels of inhibitor become undetectable 
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